Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis reveals mifamurtide improved event-free survival in localized osteosarcoma patients, suggesting a potential role in treatment.

Mifamurtide administration significantly improved 5-year event-free survival compared to chemotherapy alone, indicating its possible benefit in localized osteosarcoma.
Five-year event-free survival was 71.4% for patients receiving mifamurtide versus 58.3% without it, with a P-value of .0139, though not confirmed at multivariable analysis.
Patients aged ≤40 years with Pgp-positive tumors who received mifamurtide, combined with high-dose ifosfamide, showed promising outcomes in this merged analysis from Italy and Spain.
A total of 398 patients were analyzed, with median follow-up of 70 months, demonstrating the potential of mifamurtide after preoperative chemotherapy and surgery.

Palmerini et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals mifamurtide improved event-free survival in localized osteosarcoma patients, suggesting a potential role in treatment.